The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
about
Clinical risk-stratification for prostate cancer: Where are we, and where do we need to go?An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
P2860
The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The Cancer of the Prostate Ris ...... dose rate (LDR) brachytherapy.
@en
type
label
The Cancer of the Prostate Ris ...... dose rate (LDR) brachytherapy.
@en
prefLabel
The Cancer of the Prostate Ris ...... dose rate (LDR) brachytherapy.
@en
P2093
P2860
P356
P1433
P1476
The Cancer of the Prostate Ris ...... dose rate (LDR) brachytherapy.
@en
P2093
Daniel Taussky
Guila Delouya
Jean-Paul Bahary
Sandra Larrivée
Vimal Krishnan
P2860
P304
P356
10.1111/BJU.12587
P577
2014-03-14T00:00:00Z